In Vitro Colorectal Cancer Screening Tests Market
In-vitro Colorectal Cancer Screening Tests Market Forecasts to 2032 - Global Analysis By Test Type (Fecal Occult Blood Test (FOBT), Stool DNA Test (sDNA), Biomarker Tests (Blood-based Tests) and Other Test Types), Imaging Type (Colonoscopy, Proctoscopy, CT Scan, Ultrasound, PET Scan and MRI), Mode of Offering, Application, End User and By Geography
According to Stratistics MRC, the Global In-vitro Colorectal Cancer Screening Tests Market is accounted for $1.29 billion in 2025 and is expected to reach $2.17 billion by 2032 growing at a CAGR of 7.7% during the forecast period. In-vitro colorectal cancer screening tests are non-invasive diagnostic procedures that analyze biological samples typically stool or blood outside the body to detect early signs of colorectal cancer. These tests identify biomarkers such as occult blood, DNA mutations, or protein indicators associated with malignancies or precancerous polyps. Common methods include fecal occult blood tests (FOBT), fecal immunochemical tests (FIT), and DNA-based assays. Designed for routine screening, they support early detection, improve treatment outcomes, and reduce mortality by identifying cancer before symptoms appear
According to article in The Lancet Oncology, multitarget stool DNA tests (such as Cologuard) showed a sensitivity of over 90% for detecting colorectal cancer and around 42% for advanced adenomas.
Market Dynamics:
Driver:
Rising incidence and prevalence of colorectal cancer
Early detection is becoming a top priority for healthcare providers aiming to improve patient outcomes and reduce treatment costs. As public health programs continue emphasizing routine screening for individuals aged 45 and above, test volumes are expected to rise substantially. Moreover, awareness initiatives by cancer associations and governmental bodies are bolstering demand for non-invasive testing. This trend is further supported by the growing recognition of screening as a preventive strategy rather than a reactive measure.
Restraint:
Lower sensitivity and specificity of traditional tests
Conventional screening options, such as guaiac-based tests or outdated fecal assays, often suffer from limited sensitivity and specificity, resulting in false positives or missed diagnoses. These shortcomings can erode clinician and patient confidence in the tests, discouraging adoption in favor of more definitive diagnostics like colonoscopy. Additionally, the risk of under-detection due to low biomarker visibility may lead to disease progression in asymptomatic patients.
Opportunity:
Expansion into underserved and low-resource settings
Populations in rural or low-resource settings often lack access to advanced diagnostic infrastructure, creating a large untapped market. Portable, self-administered kits that require minimal expertise can bridge this gap, especially when distributed through government-backed community health programs. As public-private partnerships expand, stakeholders are increasingly focused on improving healthcare equity by tailoring screening solutions to diverse socioeconomic contexts.
Threat:
Misinterpretation of results and over-diagnosis/under-diagnosis
Inaccurate results may lead to over-diagnosis, subjecting patients to invasive interventions, or under-diagnosis, delaying treatment and worsening prognosis. Variability in test performance across populations adds to clinical complexity, requiring cautious application and expert oversight. Additionally, non-standardized guidelines across healthcare systems contribute to confusion in result interpretation and follow-up protocols. These factors heighten liability concerns and emphasize the need for clinician training and better validation protocols.
Covid-19 Impact:
The COVID-19 pandemic introduced disruptions to cancer screening services worldwide, delaying early diagnosis of colorectal conditions. Lockdowns and restricted hospital access led to a decline in routine check-ups, causing a backlog of undiagnosed cases. On the other hand, the pandemic highlighted the value of home-based and remote diagnostics, prompting renewed interest in self-collection kits and telehealth-integrated testing. This shift in behavior is likely to have lasting effects on screening strategies and could serve as a growth accelerator for in-vitro solutions.
The fecal occult blood test (FOBT) segment is expected to be the largest during the forecast period
The fecal occult blood test (FOBT) segment is expected to account for the largest market share during the forecast period due to its cost-effectiveness, wide availability, and non-invasive nature. Used as a frontline screening tool in numerous national cancer prevention programs, FOBTs are easily distributed and administered. Their convenience and minimal infrastructure requirements make them ideal for large-scale deployments across both developed and emerging markets.
The marcareplex segment is expected to have the highest CAGR during the forecast period
Over the forecast period, the marcareplex segment is predicted to witness the highest growth rate driven by its multiplex biomarker approach and high diagnostic precision. These advanced assays can detect multiple cancer-specific markers simultaneously, providing a more comprehensive risk assessment. Their efficiency in identifying early-stage malignancies makes them attractive for clinical labs seeking accurate yet scalable testing solutions.
Region with largest share:
During the forecast period, the North America region is expected to hold the largest market share attributed to well-established screening guidelines and expansive health coverage systems. Widespread awareness campaigns and proactive screening initiatives by agencies like the CDC and ACS have boosted participation rates across demographics. Strong funding for cancer prevention research and early technology adoption further enhance the regional market outlook.
Region with highest CAGR:
Over the forecast period, the Europe region is anticipated to exhibit the highest CAGR owing to increased public health initiatives and growing emphasis on preventive diagnostics. Countries such as Germany, the U.K., and France are expanding national cancer screening programs to include high-risk populations. Technological innovation, particularly in biomarker discovery and AI-driven analytics, is gaining traction in the region’s med-tech ecosystem.
Key players in the market
Some of the key players in In-vitro Colorectal Cancer Screening Tests Market include Sysmex Corporation, Siemens Healthcare GmbH, Randox Laboratories Ltd., Quest Diagnostics Incorporated, OncoCyte Corporation, Merck KGaA, Kyowa Kirin Co., Ltd., Invitae Corporation, Immunostics Inc., Illumina, Inc., Hologic, Inc., Genomic Health, Inc., F. Hoffmann-La Roche AG, Exact Sciences Corporation, Epigenomics AG, Eiken Chemical Co., Ltd., Bio-Rad Laboratories, Inc., Beckman Coulter Inc. and Abbott Laboratories.
Key Developments:
In June 2025, Illumina agreed to buy proteomics company SomaLogic for $350?million plus milestones, bolstering its multiomics capabilities. The deal enhances its strategy across genomics, proteomics, and personalized medicine
In May 2025, Siemens Healthineers launched the first U.S. Mobile Stroke Unit equipped with a Somatom?On.site CT scanner to deliver advanced stroke diagnostics at UCLA Health. This rapid-response ambulance aims to reduce treatment delays and improve outcomes.
Test Types Covered:
• Fecal Occult Blood Test (FOBT)
• Stool DNA Test (sDNA)
• Biomarker Tests (Blood-based Tests)
• Other Test Types
Imaging Types Covered:
• Colonoscopy
• Proctoscopy
• CT Scan
• Ultrasound
• PET Scan
• MRI
Mode of Offerings Covered:
• Physician-Led Screening
• Direct-to-Consumer (DTC) Home Testing
Applications Covered:
• MarCarePlex
• Cologic
• Colox
• miRDIGN
• PanCDx
• MeSorce CRC
End Users Covered:
• Hospitals
• Clinics
• Diagnostic Laboratories
• Ambulatory Surgical Centers
• Other End Users
Regions Covered:
• North America
o US
o Canada
o Mexico
• Europe
o Germany
o UK
o Italy
o France
o Spain
o Rest of Europe
• Asia Pacific
o Japan
o China
o India
o Australia
o New Zealand
o South Korea
o Rest of Asia Pacific
• South America
o Argentina
o Brazil
o Chile
o Rest of South America
• Middle East & Africa
o Saudi Arabia
o UAE
o Qatar
o South Africa
o Rest of Middle East & Africa
What our report offers:
- Market share assessments for the regional and country-level segments
- Strategic recommendations for the new entrants
- Covers Market data for the years 2024, 2025, 2026, 2028, and 2032
- Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
- Strategic recommendations in key business segments based on the market estimations
- Competitive landscaping mapping the key common trends
- Company profiling with detailed strategies, financials, and recent developments
- Supply chain trends mapping the latest technological advancements
Free Customization Offerings:
All the customers of this report will be entitled to receive one of the following free customization options:
• Company Profiling
o Comprehensive profiling of additional market players (up to 3)
o SWOT Analysis of key players (up to 3)
• Regional Segmentation
o Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
• Competitive Benchmarking
o Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances
Table of Contents
1 Executive Summary
2 Preface
2.1 Abstract
2.2 Stake Holders
2.3 Research Scope
2.4 Research Methodology
2.4.1 Data Mining
2.4.2 Data Analysis
2.4.3 Data Validation
2.4.4 Research Approach
2.5 Research Sources
2.5.1 Primary Research Sources
2.5.2 Secondary Research Sources
2.5.3 Assumptions
3 Market Trend Analysis
3.1 Introduction
3.2 Drivers
3.3 Restraints
3.4 Opportunities
3.5 Threats
3.6 Application Analysis
3.7 End User Analysis
3.8 Emerging Markets
3.9 Impact of Covid-19
4 Porters Five Force Analysis
4.1 Bargaining power of suppliers
4.2 Bargaining power of buyers
4.3 Threat of substitutes
4.4 Threat of new entrants
4.5 Competitive rivalry
5 Global In-vitro Colorectal Cancer Screening Tests Market, By Test Type
5.1 Introduction
5.2 Fecal Occult Blood Test (FOBT)
5.2.1 Guaiac FOBT (gFOBT)
5.2.2 Fecal Immunochemical Test (FIT or iFOBT)
5.3 Stool DNA Test (sDNA)
5.3.1 Multitarget Stool DNA Testing
5.3.2 Methylated Gene Testing
5.3.3 Panel DNA Tests
5.4 Biomarker Tests (Blood-based Tests)
5.4.1 Tumor M2-PK Stool Test
5.4.2 Transferrin Assays
5.4.3 Plasma Methylated SEPT9 DNA Assay
5.4.4 Liquid Biopsy
5.5 Other Test Types
6 Global In-vitro Colorectal Cancer Screening Tests Market, By Imaging Type
6.1 Introduction
6.2 Colonoscopy
6.3 Proctoscopy
6.4 CT Scan
6.5 Ultrasound
6.6 PET Scan
6.7 MRI
7 Global In-vitro Colorectal Cancer Screening Tests Market, By Mode of Offering
7.1 Introduction
7.2 Physician-Led Screening
7.3 Direct-to-Consumer (DTC) Home Testing
8 Global In-vitro Colorectal Cancer Screening Tests Market, By Application
8.1 Introduction
8.2 MarCarePlex
8.3 Cologic
8.4 Colox
8.5 miRDIGN
8.6 PanCDx
8.7 MeSorce CRC
9 Global In-vitro Colorectal Cancer Screening Tests Market, By End User
9.1 Introduction
9.2 Hospitals
9.3 Clinics
9.4 Diagnostic Laboratories
9.5 Ambulatory Surgical Centers
9.6 Other End Users
10 Global In-vitro Colorectal Cancer Screening Tests Market, By Geography
10.1 Introduction
10.2 North America
10.2.1 US
10.2.2 Canada
10.2.3 Mexico
10.3 Europe
10.3.1 Germany
10.3.2 UK
10.3.3 Italy
10.3.4 France
10.3.5 Spain
10.3.6 Rest of Europe
10.4 Asia Pacific
10.4.1 Japan
10.4.2 China
10.4.3 India
10.4.4 Australia
10.4.5 New Zealand
10.4.6 South Korea
10.4.7 Rest of Asia Pacific
10.5 South America
10.5.1 Argentina
10.5.2 Brazil
10.5.3 Chile
10.5.4 Rest of South America
10.6 Middle East & Africa
10.6.1 Saudi Arabia
10.6.2 UAE
10.6.3 Qatar
10.6.4 South Africa
10.6.5 Rest of Middle East & Africa
11 Key Developments
11.1 Agreements, Partnerships, Collaborations and Joint Ventures
11.2 Acquisitions & Mergers
11.3 New Product Launch
11.4 Expansions
11.5 Other Key Strategies
12 Company Profiling
12.1 Sysmex Corporation
12.2 Siemens Healthcare GmbH
12.3 Randox Laboratories Ltd.
12.4 Quest Diagnostics Incorporated
12.5 OncoCyte Corporation
12.6 Merck KGaA
12.7 Kyowa Kirin Co., Ltd.
12.8 Invitae Corporation
12.9 Immunostics Inc.
12.10 Illumina, Inc.
12.11 Hologic, Inc.
12.12 Genomic Health, Inc.
12.13 F. Hoffmann-La Roche AG
12.14 Exact Sciences Corporation
12.15 Epigenomics AG
12.16 Eiken Chemical Co., Ltd.
12.17 Bio-Rad Laboratories, Inc.
12.18 Beckman Coulter Inc.
12.19 Abbott Laboratories
List of Tables
1 Global In-vitro Colorectal Cancer Screening Tests Market Outlook, By Region (2024-2032) ($MN)
2 Global In-vitro Colorectal Cancer Screening Tests Market Outlook, By Test Type (2024-2032) ($MN)
3 Global In-vitro Colorectal Cancer Screening Tests Market Outlook, By Fecal Occult Blood Test (FOBT) (2024-2032) ($MN)
4 Global In-vitro Colorectal Cancer Screening Tests Market Outlook, By Guaiac FOBT (gFOBT) (2024-2032) ($MN)
5 Global In-vitro Colorectal Cancer Screening Tests Market Outlook, By Fecal Immunochemical Test (FIT or iFOBT) (2024-2032) ($MN)
6 Global In-vitro Colorectal Cancer Screening Tests Market Outlook, By Stool DNA Test (sDNA) (2024-2032) ($MN)
7 Global In-vitro Colorectal Cancer Screening Tests Market Outlook, By Multitarget Stool DNA Testing (2024-2032) ($MN)
8 Global In-vitro Colorectal Cancer Screening Tests Market Outlook, By Methylated Gene Testing (2024-2032) ($MN)
9 Global In-vitro Colorectal Cancer Screening Tests Market Outlook, By Panel DNA Tests (2024-2032) ($MN)
10 Global In-vitro Colorectal Cancer Screening Tests Market Outlook, By Biomarker Tests (Blood-based Tests) (2024-2032) ($MN)
11 Global In-vitro Colorectal Cancer Screening Tests Market Outlook, By Tumor M2-PK Stool Test (2024-2032) ($MN)
12 Global In-vitro Colorectal Cancer Screening Tests Market Outlook, By Transferrin Assays (2024-2032) ($MN)
13 Global In-vitro Colorectal Cancer Screening Tests Market Outlook, By Plasma Methylated SEPT9 DNA Assay (2024-2032) ($MN)
14 Global In-vitro Colorectal Cancer Screening Tests Market Outlook, By Liquid Biopsy (2024-2032) ($MN)
15 Global In-vitro Colorectal Cancer Screening Tests Market Outlook, By Other Test Types (2024-2032) ($MN)
16 Global In-vitro Colorectal Cancer Screening Tests Market Outlook, By Imaging Type (2024-2032) ($MN)
17 Global In-vitro Colorectal Cancer Screening Tests Market Outlook, By Colonoscopy (2024-2032) ($MN)
18 Global In-vitro Colorectal Cancer Screening Tests Market Outlook, By Proctoscopy (2024-2032) ($MN)
19 Global In-vitro Colorectal Cancer Screening Tests Market Outlook, By CT Scan (2024-2032) ($MN)
20 Global In-vitro Colorectal Cancer Screening Tests Market Outlook, By Ultrasound (2024-2032) ($MN)
21 Global In-vitro Colorectal Cancer Screening Tests Market Outlook, By PET Scan (2024-2032) ($MN)
22 Global In-vitro Colorectal Cancer Screening Tests Market Outlook, By MRI (2024-2032) ($MN)
23 Global In-vitro Colorectal Cancer Screening Tests Market Outlook, By Mode of Offering (2024-2032) ($MN)
24 Global In-vitro Colorectal Cancer Screening Tests Market Outlook, By Physician-Led Screening (2024-2032) ($MN)
25 Global In-vitro Colorectal Cancer Screening Tests Market Outlook, By Direct-to-Consumer (DTC) Home Testing (2024-2032) ($MN)
26 Global In-vitro Colorectal Cancer Screening Tests Market Outlook, By Application (2024-2032) ($MN)
27 Global In-vitro Colorectal Cancer Screening Tests Market Outlook, By MarCarePlex (2024-2032) ($MN)
28 Global In-vitro Colorectal Cancer Screening Tests Market Outlook, By Cologic (2024-2032) ($MN)
29 Global In-vitro Colorectal Cancer Screening Tests Market Outlook, By Colox (2024-2032) ($MN)
30 Global In-vitro Colorectal Cancer Screening Tests Market Outlook, By miRDIGN (2024-2032) ($MN)
31 Global In-vitro Colorectal Cancer Screening Tests Market Outlook, By PanCDx (2024-2032) ($MN)
32 Global In-vitro Colorectal Cancer Screening Tests Market Outlook, By MeSorce CRC (2024-2032) ($MN)
33 Global In-vitro Colorectal Cancer Screening Tests Market Outlook, By End User (2024-2032) ($MN)
34 Global In-vitro Colorectal Cancer Screening Tests Market Outlook, By Hospitals (2024-2032) ($MN)
35 Global In-vitro Colorectal Cancer Screening Tests Market Outlook, By Clinics (2024-2032) ($MN)
36 Global In-vitro Colorectal Cancer Screening Tests Market Outlook, By Diagnostic Laboratories (2024-2032) ($MN)
37 Global In-vitro Colorectal Cancer Screening Tests Market Outlook, By Ambulatory Surgical Centers (2024-2032) ($MN)
38 Global In-vitro Colorectal Cancer Screening Tests Market Outlook, By Other End Users (2024-2032) ($MN)
Note: Tables for North America, Europe, APAC, South America, and Middle East & Africa Regions are also represented in the same manner as above.
List of Figures
RESEARCH METHODOLOGY
We at ‘Stratistics’ opt for an extensive research approach which involves data mining, data validation, and data analysis. The various research sources include in-house repository, secondary research, competitor’s sources, social media research, client internal data, and primary research.
Our team of analysts prefers the most reliable and authenticated data sources in order to perform the comprehensive literature search. With access to most of the authenticated data bases our team highly considers the best mix of information through various sources to obtain extensive and accurate analysis.
Each report takes an average time of a month and a team of 4 industry analysts. The time may vary depending on the scope and data availability of the desired market report. The various parameters used in the market assessment are standardized in order to enhance the data accuracy.
Data Mining
The data is collected from several authenticated, reliable, paid and unpaid sources and is filtered depending on the scope & objective of the research. Our reports repository acts as an added advantage in this procedure. Data gathering from the raw material suppliers, distributors and the manufacturers is performed on a regular basis, this helps in the comprehensive understanding of the products value chain. Apart from the above mentioned sources the data is also collected from the industry consultants to ensure the objective of the study is in the right direction.
Market trends such as technological advancements, regulatory affairs, market dynamics (Drivers, Restraints, Opportunities and Challenges) are obtained from scientific journals, market related national & international associations and organizations.
Data Analysis
From the data that is collected depending on the scope & objective of the research the data is subjected for the analysis. The critical steps that we follow for the data analysis include:
- Product Lifecycle Analysis
- Competitor analysis
- Risk analysis
- Porters Analysis
- PESTEL Analysis
- SWOT Analysis
The data engineering is performed by the core industry experts considering both the Marketing Mix Modeling and the Demand Forecasting. The marketing mix modeling makes use of multiple-regression techniques to predict the optimal mix of marketing variables. Regression factor is based on a number of variables and how they relate to an outcome such as sales or profits.
Data Validation
The data validation is performed by the exhaustive primary research from the expert interviews. This includes telephonic interviews, focus groups, face to face interviews, and questionnaires to validate our research from all aspects. The industry experts we approach come from the leading firms, involved in the supply chain ranging from the suppliers, distributors to the manufacturers and consumers so as to ensure an unbiased analysis.
We are in touch with more than 15,000 industry experts with the right mix of consultants, CEO's, presidents, vice presidents, managers, experts from both supply side and demand side, executives and so on.
The data validation involves the primary research from the industry experts belonging to:
- Leading Companies
- Suppliers & Distributors
- Manufacturers
- Consumers
- Industry/Strategic Consultants
Apart from the data validation the primary research also helps in performing the fill gap research, i.e. providing solutions for the unmet needs of the research which helps in enhancing the reports quality.
For more details about research methodology, kindly write to us at info@strategymrc.com
Frequently Asked Questions
In case of any queries regarding this report, you can contact the customer service by filing the “Inquiry Before Buy” form available on the right hand side. You may also contact us through email: info@strategymrc.com or phone: +1-301-202-5929
Yes, the samples are available for all the published reports. You can request them by filling the “Request Sample” option available in this page.
Yes, you can request a sample with your specific requirements. All the customized samples will be provided as per the requirement with the real data masked.
All our reports are available in Digital PDF format. In case if you require them in any other formats, such as PPT, Excel etc you can submit a request through “Inquiry Before Buy” form available on the right hand side. You may also contact us through email: info@strategymrc.com or phone: +1-301-202-5929
We offer a free 15% customization with every purchase. This requirement can be fulfilled for both pre and post sale. You may send your customization requirements through email at info@strategymrc.com or call us on +1-301-202-5929.
We have 3 different licensing options available in electronic format.
- Single User Licence: Allows one person, typically the buyer, to have access to the ordered product. The ordered product cannot be distributed to anyone else.
- 2-5 User Licence: Allows the ordered product to be shared among a maximum of 5 people within your organisation.
- Corporate License: Allows the product to be shared among all employees of your organisation regardless of their geographical location.
All our reports are typically be emailed to you as an attachment.
To order any available report you need to register on our website. The payment can be made either through CCAvenue or PayPal payments gateways which accept all international cards.
We extend our support to 6 months post sale. A post sale customization is also provided to cover your unmet needs in the report.
Request Customization
We offer complimentary customization of up to 15% with every purchase. To share your customization requirements, feel free to email us at info@strategymrc.com or call us on +1-301-202-5929. .
Please Note: Customization within the 15% threshold is entirely free of charge. If your request exceeds this limit, we will conduct a feasibility assessment. Following that, a detailed quote and timeline will be provided.
WHY CHOOSE US ?
Assured Quality
Best in class reports with high standard of research integrity
24X7 Research Support
Continuous support to ensure the best customer experience.
Free Customization
Adding more values to your product of interest.
Safe & Secure Access
Providing a secured environment for all online transactions.
Trusted by 600+ Brands
Serving the most reputed brands across the world.
